244 related articles for article (PubMed ID: 17192298)
1. The effect of growth hormone on the response of total and acylated ghrelin to a standardized oral glucose load and insulin resistance in children with Prader-Willi syndrome.
Hauffa BP; Haase K; Range IM; Unger N; Mann K; Petersenn S
J Clin Endocrinol Metab; 2007 Mar; 92(3):834-40. PubMed ID: 17192298
[TBL] [Abstract][Full Text] [Related]
2. Suppression of acylated ghrelin during oral glucose tolerance test is correlated with whole-body insulin sensitivity in children with Prader-Willi syndrome.
Paik KH; Choe YH; Park WH; Oh YJ; Kim AH; Chu SH; Kim SW; Kwon EK; Han SJ; Shon WY; Jin DK
J Clin Endocrinol Metab; 2006 May; 91(5):1876-81. PubMed ID: 16507634
[TBL] [Abstract][Full Text] [Related]
3. Obestatin is not elevated or correlated with insulin in children with Prader-Willi syndrome.
Park WH; Oh YJ; Kim GY; Kim SE; Paik KH; Han SJ; Kim AH; Chu SH; Kwon EK; Kim SW; Jin DK
J Clin Endocrinol Metab; 2007 Jan; 92(1):229-34. PubMed ID: 17047025
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of a normal meal-induced decrease in plasma ghrelin levels in children with Prader-Willi syndrome.
Bizzarri C; Rigamonti AE; Giannone G; Berardinelli R; Cella SG; Cappa M; Müller EE
Horm Metab Res; 2004 Mar; 36(3):164-9. PubMed ID: 15057669
[TBL] [Abstract][Full Text] [Related]
5. Adiponectin levels in prepubertal children with Prader-Willi syndrome before and during growth hormone therapy.
Festen DA; van Toorenenbergen A; Duivenvoorden HJ; Hokken-Koelega AC
J Clin Endocrinol Metab; 2007 Apr; 92(4):1549-54. PubMed ID: 17264186
[TBL] [Abstract][Full Text] [Related]
6. Hyperghrelinemia is a common feature of Prader-Willi syndrome and pituitary stalk interruption: a pathophysiological hypothesis.
Tauber M; Conte Auriol F; Moulin P; Molinas C; Delagnes V; Salles JP
Horm Res; 2004; 62(1):49-54. PubMed ID: 15192277
[TBL] [Abstract][Full Text] [Related]
7. Carbohydrate metabolism is not impaired after 3 years of growth hormone therapy in children with Prader-Willi syndrome.
L'Allemand D; Eiholzer U; Schlumpf M; Torresani T; Girard J
Horm Res; 2003; 59(5):239-48. PubMed ID: 12714788
[TBL] [Abstract][Full Text] [Related]
8. Circulating ghrelin levels are suppressed by meals and octreotide therapy in children with Prader-Willi syndrome.
Haqq AM; Stadler DD; Rosenfeld RG; Pratt KL; Weigle DS; Frayo RS; LaFranchi SH; Cummings DE; Purnell JQ
J Clin Endocrinol Metab; 2003 Aug; 88(8):3573-6. PubMed ID: 12915638
[TBL] [Abstract][Full Text] [Related]
9. Children with Prader-Willi syndrome exhibit more evident meal-induced responses in plasma ghrelin and peptide YY levels than obese and lean children.
Bizzarri C; Rigamonti AE; Luce A; Cappa M; Cella SG; Berini J; Sartorio A; Müller EE; Salvatoni A
Eur J Endocrinol; 2010 Mar; 162(3):499-505. PubMed ID: 20019130
[TBL] [Abstract][Full Text] [Related]
10. Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome.
Crinò A; Di Giorgio G; Manco M; Grugni G; Maggioni A
Horm Res; 2007; 68(2):83-90. PubMed ID: 17337902
[TBL] [Abstract][Full Text] [Related]
11. Influence of age, gender, and glucose tolerance on fasting and fed acylated ghrelin in Prader Willi syndrome.
Prodam F; Bellone S; Grugni G; Crinò A; Ragusa L; Franzese A; Di Battista E; Corrias A; Walker G; Rapa A; Aimaretti G; Bona G
Clin Nutr; 2009 Feb; 28(1):94-9. PubMed ID: 19150743
[TBL] [Abstract][Full Text] [Related]
12. Endocrine and metabolic aspects of adult Prader-Willi syndrome with special emphasis on the effect of growth hormone treatment.
Höybye C
Growth Horm IGF Res; 2004 Feb; 14(1):1-15. PubMed ID: 14700552
[TBL] [Abstract][Full Text] [Related]
13. Hyperghrelinemia precedes obesity in Prader-Willi syndrome.
Feigerlová E; Diene G; Conte-Auriol F; Molinas C; Gennero I; Salles JP; Arnaud C; Tauber M
J Clin Endocrinol Metab; 2008 Jul; 93(7):2800-5. PubMed ID: 18460565
[TBL] [Abstract][Full Text] [Related]
14. Acylated and unacylated ghrelin during OGTT in Prader-Willi syndrome: support for normal response to food intake.
Kuppens RJ; Delhanty PJ; Huisman TM; van der Lely AJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2016 Sep; 85(3):488-94. PubMed ID: 26850227
[TBL] [Abstract][Full Text] [Related]
15. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome.
Haqq AM; Farooqi IS; O'Rahilly S; Stadler DD; Rosenfeld RG; Pratt KL; LaFranchi SH; Purnell JQ
J Clin Endocrinol Metab; 2003 Jan; 88(1):174-8. PubMed ID: 12519848
[TBL] [Abstract][Full Text] [Related]
16. Altered distribution of adiponectin isoforms in children with Prader-Willi syndrome (PWS): association with insulin sensitivity and circulating satiety peptide hormones.
Haqq AM; Muehlbauer M; Svetkey LP; Newgard CB; Purnell JQ; Grambow SC; Freemark MS
Clin Endocrinol (Oxf); 2007 Dec; 67(6):944-51. PubMed ID: 17666087
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone treatment of children with Prader-Willi syndrome: effects on glucose and insulin homeostasis. Swedish National Growth Hormone Advisory Group.
Lindgren AC; Hagenäs L; Ritzén EM
Horm Res; 1999; 51(4):157-61. PubMed ID: 10474015
[TBL] [Abstract][Full Text] [Related]
18. Peptide YY, cholecystokinin, insulin and ghrelin response to meal did not change, but mean serum levels of insulin is reduced in children with Prader-Willi syndrome.
Paik KH; Jin DK; Lee KH; Armstrong L; Lee JE; Oh YJ; Kim S; Kwon EK; Choe YH
J Korean Med Sci; 2007 Jun; 22(3):436-41. PubMed ID: 17596650
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment.
de Lind van Wijngaarden RF; Cianflone K; Gao Y; Leunissen RW; Hokken-Koelega AC
J Clin Endocrinol Metab; 2010 Apr; 95(4):1758-66. PubMed ID: 20173020
[TBL] [Abstract][Full Text] [Related]
20. Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma.
Goldstone AP; Patterson M; Kalingag N; Ghatei MA; Brynes AE; Bloom SR; Grossman AB; Korbonits M
J Clin Endocrinol Metab; 2005 May; 90(5):2681-90. PubMed ID: 15687345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
